[G26-22] Leniolisib (APDS) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V
Last updated 23.09.2026
Project no.:
G26-22
Commission:
Commission awarded on 01.07.2026 by the Federal Joint Committee (GBA).
Report type:
Dossier assessment
Status:
Commission work started
Department/Division:
Health Economics
Note:
In accordance with §35a (1) Sentence 11 Social Code Book (SGB) V, the added medical benefit of orphan drugs is deemed as proven by the fact that they have been approved. On behalf of the Federal Joint Committee (GBA), IQWiG therefore solely assesses the information on patient numbers and costs in the pharmaceutical company's dossier.